Enasidenib: A Promising Option for IDH2-Mutated Acute Myeloid Leukemia?
The authors explored the evidence supporting the safety and side effect profile of enasidenib, FDA-approved in August 2017 for relapsed/refractory AML. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
New cancer therapy target found in mitochondria for potential treatment of blood cancers
(University of Texas M. D. Anderson Cancer Center) A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukemia (AML) and mantle cell lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 2, 2019 Category: Cancer & Oncology Source Type: news
Agios Announces FDA Approval of Tibsovo as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food and Drug Administration (FDA) approved a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 2, 2019 Category: Drugs & Pharmacology Source Type: news
Two birds, one stone: Drug combo may prove effective against second type of leukemia
(Beth Israel Deaconess Medical Center) Researchers tested to see if arsenic trioxide (ATO) was effective in combination with all-trans retinoic acid (ATRA) in in both the mouse model of acute myeloid leukemia (AML) and in human AML cells in the lab, and determined that the combination proved 'powerfully and exquisitely effective' against a subset of AML. The combo could serve as the foothold researchers need to overcome resistance to therapy -- a common challenge in treating AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news
Overlooked molecular machine in cell nucleus may hold key to treating aggressive leukemia
(Cincinnati Children's Hospital Medical Center) Many people fighting a very aggressive form of acute myeloid leukemia (AML) don't survive more than five years. These very sick patients are often unable to receive the only cure -- a bone marrow transplant. Now, an international team of scientists report in Nature Cell Biology on a long-overlooked part of a leukemic cell's internal machinery, where they may have found a key to treating the aggressive blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 22, 2019 Category: Cancer & Oncology Source Type: news
